10-Q · May 15, 2026
TransCode Therapeutics reported Q4 2025 results showing significant challenges, including zero revenue and a diluted EPS of -18.1. The company announced operational and financial shifts following the acquisition of…
Earnings analysis · 10-Q
RNAZ earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
TransCode remains a pre-commercial biotechnology company with $0 revenue and diluted EPS of -$7.17 for the quarter. Liquidity is constrained: management reported approximately $8.4 million of cash at June 30, 2026,…
Read full summary
TransCode remains a pre-commercial biotechnology company with $0 revenue and diluted EPS of -$7.17 for the quarter. Liquidity is constrained: management reported approximately $8.4 million of cash at June 30, 2026, expects funding to last only through approximately year-end 2026, and states that additional capital is needed to continue as a going concern. Nasdaq equity compliance improved after preferred-stock conversions, but listing risk, an unremediated material weakness, and potential litigation exposure of up to approximately $9.2 million remain material negatives.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-7.17
What stood out
-
No revenue; EPS remained negative
The company reported no revenue for the quarter and diluted EPS of -$7.17, reflecting its continued pre-commercial, development-stage profile.
-
Nasdaq equity compliance improved
Nasdaq confirmed that, following conversion of all outstanding preferred stock into common stock between July 20 and August 10, 2026, the company believes it exceeds the minimum stockholders’ equity requirement.
-
Wheeler dispute moved to arbitration
The Wheeler litigation was compelled to arbitration on July 30, 2026, and the court stayed the litigation pending a final arbitration decision.
-
Control remediation is underway
Management identified remediation actions including new accounting software, more robust accounting policies and procedures, and additional finance and accounting personnel and consultants.
What to watch
-
Additional funding is required
The company had approximately $8.4 million of cash at June 30, 2026, and stated that it will need to raise additional capital to continue as a going concern; current funds and expected Second Convertible Note proceeds are expected to support operations only through approximately year-end 2026.
-
Listing and control deficiencies remain
The company disclosed that its stockholders’ equity did not meet Nasdaq continued-listing rules and that a material weakness in internal control over financial reporting from the 2025 Annual Report still exists; management cannot reasonably estimate when remediation will be completed.
-
Potential $9.2 million litigation exposure
Wheeler’s lawsuit seeks compensatory and punitive damages, restitution, interest, and fees involving as much as approximately $9.2 million, although the company disputes the claims and the matter is now stayed pending arbitration.
-
Concentrated control limits governance
CKLS, through DEFJ, beneficially owned approximately 83.5% of the voting power as of August 10, 2026, allowing it to significantly influence the board, business plans, and stockholder matters.
-
Unhedged foreign-exchange exposure
The company recognized foreign-currency transaction losses of approximately $36 thousand for the three months ended June 30, 2026, and $58 thousand for the six months ended June 30, 2026, and has entered into no foreign-currency hedging contracts.
Management's outlook
No quantitative revenue or EPS guidance was provided in the filing. Management states that approximately $8.4 million of cash, together with expected proceeds from the Second Convertible Note under the SEPA, is expected to support operating expenses and capital expenditures through approximately year-end 2026.
Earlier filings 4
10-K · April 30, 2026
TransCode Therapeutics, a clinical-stage company in the RNA therapeutic field, highlighted the completion of its acquisition of Polynoma and a substantial financing arrangement that raised approximately $25 million.…
10-K · April 15, 2026
TransCode Therapeutics is a clinical-stage immuno-oncology / RNA therapeutics company whose lead candidate TTX‑MC138 has completed a Phase 1a trial and a Phase I/II study commenced in the third quarter of 2024. During…
10-Q · November 14, 2025
TransCode reported no revenue and a quarterly net loss of $4,856,051 (EPS -$5.82) for the three months ended September 30, 2025, driven by higher R&D and G&A spending. Cash declined to $2,835,916 at 9/30/2025 and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.